Introduction A significant decrease in red blood cell (RBC) survival has been observed in
patients with renal failure, which is supposed to contribute to renal anemia. The aim of this …

Background Reduced survival of red blood cells (RBCs) in patients with chronic kidney
disease (CKD) is thought to contribute to renal anaemia. Although renal anaemia improved …

Background Renal anemia is a common complication in patients with end-stage renal
disease (ESRD). Both roxadustat and recombinant human erythropoietin (rhEPO) are …

Introduction Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase
inhibitor being developed for the treatment of anemia of chronic kidney disease (CKD). This …

Background We evaluated the efficacy and safety of roxadustat versus epoetin alfa for the
treatment of chronic kidney disease-related anemia in patients new to dialysis. Methods …

Background Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl-hydroxylase
inhibitor that promotes erythropoiesis through increasing endogenous erythropoietin …

Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor for the treatment
of anemia in chronic kidney disease (CKD). Emerging evidence suggests that roxadustat …

Background Concerns regarding cardiovascular safety with current treatments for anemia in
patients with dialysis-dependent (DD)-CKD have encouraged the development of …

Introduction Erythropoiesis-stimulating agents, standard of care for anemia of end-stage
kidney disease, are associated with cardiovascular events. We evaluated the efficacy and …

Background Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that
stimulates erythropoiesis and regulates iron metabolism. Additional data are needed …